Table 1 Comparison of baseline characteristics between NAFLD group and control group

n (%)

210

65

-

Age, y, mean ± SD

35.62(± 16.217)

38.00(± 13.959)

0.448

Sex(male), n (%)

90(42.9)

38(58.5)

0.028*

Clinical features, mean ± SD

 Heart rate, bpm

78.63(± 6.872)

78.62(± 6.232)

0.912

 SBP, mmHg

129.57(± 14.914)

134.17(± 17.335)

0.146

 DBP, mmHg

81.19(± 10.586)

82.78(± 11.013)

0.716

 BMI, kg/m2

23.85(± 4.551)

27.07(± 4.647)

< 0.001*

History of risk factor, n (%)

 Hypertension

69(32.9)

23(35.4)

0.706

 Diabetes

28 (13.3)

11(18.5)

0.305

 Hypercholesterolemia

27(12.9)

9(13.8)

0.836

 Smoking

31(14.8)

15(23.1)

0.116

Laboratory results, median (IQR)

 WBC count, 10⁹/L

7.04(2.27)

6.61(3.52)

1.000

 LY count, 10⁹/L

1.91(0.92)

1.89(0.91)

0.851

 PLT count, 10⁹/L

256.00(84)

256(56)

0.672

 HDL-C, mmol/L

1.30(0.40)

1.14(0.33)

0.002*

 LDL-C, mmol/L

2.185(1.20)

2.20(1.55)

0.871

 Hcy µmol/L

12.10(6.42)

12.87(6.57)

0.308

 ALT, U/L

16.95(15.3)

25.4(27.9)

< 0.001*

 AST, U/L

17.00(6.2)

20.00(13.9)

0.003*

 GGT, mmol/L

19.00(16.0)

27.50(20.7)

< 0.001*

 Cr, µmol/L

52.85(20.9)

53.70(24.5)

0.180

 UA, µmol/L

294.95(108.9)

351.20(117.5)

< 0.001*

 TG, mmol/L

1.055(0.71)

1.53(1.21)

< 0.001*

 TC, mmol/L

3.93(1.38)

4.21(1.53)

0.815

 ApoA, g/L

1.295(0.31)

1.21(0.32)

0.087

 ApoB, g/L

0.78(0.26)

0.82(0.34)

0.228

Primary symptom n (%)

0.707

 Infarction

83(39.5)

24(36.9)

 Non-infarction

127(60.5)

41(63.1)

Suzuki stage, n (%)

0.425

 1–3

151(71.9)

50(76.9)

 4–6

59(28.1)

15(23.1)

Surgical option, n (%)

0.950

 Direct bypass

96(45.7)

30(46.2)

 Indirect bypass

114(54.3)

35(53.8)

Admission mRS, n (%)

0.858

 0–2

189(90)

58(89.8)

 3–5

21(10)

7(10.2)